Metadata record for the manuscript: A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial
István Peták, Maud Kamal, Anna Dirner, Ivan Bièche, Róbert Dóczi, Odette Mariani, Péter Filotás, Anne Vincent‐Salomon, Barbara Vodicska, Vincent Servois, Edit Várkondi, David Gentien, Dóra Tihanyi, Patricia Tresca, Dóra Lakatos, Nicolas Servant, Júlia Déri, Pauline du Rusquec, Csilla Hegedüs, Diana Bello Roufai · Figshare · 2021
Summary This metadata record provides details of the data supporting the claims of the related manuscript: “A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial”. The related study developed an artificial intelligence (AI)-assisted computational method, the digital drug-assignment (DDA) system, to prioritise potential molecularly targeted agents (MTAs) for each cancer patient based on the complex individual molecular profile of their tumour. Type of data: potential MTAs for cancer patients based on the complex individual molecular profile of their tumour; AI computationally generated data Subject of data: Homo sapiens Sample size: 113 Recruitment: patients available from the SHIVA01 clinical trial Data access The data supporting the findings of the related study are available within the paper and/or uploaded in reusable format to the figshare repository, and are openly available at: https://doi.org/10.6084/m9.figshare.14331323. A list of which data file underlies which figure and table of the related article is available in the file ‘Petak_et_al_2021_underlying_data_list.xlsx’, which is shared together with this data record. Corresponding author(s) for this study Istvan Petak, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Hungary. [email protected]. Study approval The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of the National Institute of Pharmacy and Nutrition (approval ID: OGYEI/50268/2017). The SHIVA01 clinical trial was approved by the Ile-de-France ethics committee. The trial was carried out in accordance with the Declaration of Helsinki, the Good Clinical Practice guidelines of the International Conference on Harmonization, and relevant French and European laws and directives.